GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Implantica AG (OSTO:IMP A SDB) » Definitions » Ending Cash Position

Implantica AG (OSTO:IMP A SDB) Ending Cash Position : kr0.00 Mil (As of . 20)


View and export this data going back to 2020. Start your Free Trial

What is Implantica AG Ending Cash Position?

Implantica AG's Ending Cash Position for the quarter that ended in . 20 was kr0.00 Mil.


Implantica AG Ending Cash Position Historical Data

The historical data trend for Implantica AG's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Implantica AG Ending Cash Position Chart

Implantica AG Annual Data
Trend
Ending Cash Position

Implantica AG Semi-Annual Data
Ending Cash Position

Implantica AG Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Implantica AG's Ending Cash Position for the fiscal year that ended in . 20 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=+
=0.00

Implantica AG's Ending Cash Position for the quarter that ended in . 20 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=+
=0.00


Implantica AG Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Implantica AG's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Implantica AG Business Description

Comparable Companies
Traded in Other Exchanges
Address
Aeulestrasse 45, Vaduz, LIE, 9490
Implantica AG is a medtech group providing effective care for serious health conditions and improving patients' quality of life by bringing advanced technology into the body. The therapies Implantica develops are based on implants that are medical devices inserted into the patient's body and are intended to remain in place permanently or semi-permanently, using electrical power provided by a battery. The company has developed a broad, patent-protected, product pipeline based partly on its two platform technologies. Its lead product, RefluxStop, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results.

Implantica AG Headlines

No Headlines